First patient dosed in Deciphera’s Phase III INTREPID study

Deciphera Pharmaceuticals has dosed the first patient in its global pivotal Phase III INTREPID study, evaluating sapablursen for the treatment of PV. The trial is enrolling in the US and will include regions in the Asia Pacific, Europe, Latin America, and North America. The study is for patients with phlebotomy-dependent PV and compares sapablursen to placebo over 32 weeks. Credit: Arif biswas / Shutterstock.com. Deciphera Pharmaceuticals has dosed the first patient in its global pivotal Phase III INTREPID study, evaluating sapablursen for the treatment of polycythaemia vera (PV). Sapablursen is being investigated as a potential once-monthly treatment for PV, a…

Source: Clinical Trials Arena